CGT9486 plus sunitinib + CGT9486 + Sunitinib + Sunitinib + Midazolam + CGT9486 plus sunitinib
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Gastrointestinal Stromal Tumors
Conditions
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Trial Timeline
Apr 14, 2022 → Sep 1, 2026
NCT ID
NCT05208047About CGT9486 plus sunitinib + CGT9486 + Sunitinib + Sunitinib + Midazolam + CGT9486 plus sunitinib
CGT9486 plus sunitinib + CGT9486 + Sunitinib + Sunitinib + Midazolam + CGT9486 plus sunitinib is a phase 3 stage product being developed by Cogent Biosciences for Advanced Gastrointestinal Stromal Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05208047. Target conditions include Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05208047 | Phase 3 | Active |
Competing Products
20 competing products in Advanced Gastrointestinal Stromal Tumors